
Clinical Trials Tech Firm Science 37 to Go Private at Fraction of Past $1B Valuation
Science 37 rode the trends of Covid-19 technologies and SPAC mergers to a more than $1 billion valuation. But revenue for the decentralized clinical trials software firm stopped growing, and it’s now going private valued at just $38 million.